Biotherapeutic glycoproteins have revolutionised the field of pharmaceuticals, with new discoveries and continuous improvements underpinning the rapid growth of this industry. N-glycosylation is a critical quality attribute of biotherapeutic glycoproteins that influences the efficacy, half-life and immunogenicity of these drugs. This review will focus on the advances and future directions of remodelling N-glycosylation in Chinese hamster ovary (CHO) cells, which are the workhorse of recombinant biotherapeutic production, with particular emphasis on antibody products, using strategies such as cell line and protein backbone engineering.
CITATION STYLE
Donini, R., Haslam, S. M., & Kontoravdi, C. (2021, April 1). Glycoengineering Chinese hamster ovary cells: A short history. Biochemical Society Transactions. Portland Press Ltd. https://doi.org/10.1042/BST20200840
Mendeley helps you to discover research relevant for your work.